OMass raises $310M for rare endocrine disorder drug

OMass has secured $310 million to advance a drug candidate for congenital adrenal hyperplasia, a rare endocrine disorder with only one FDA-approved treatment, Neurocrine Biosciences’ crinecerfont. The startup’s molecule, still unnamed, is positioned as an alternative to crinecerfont, according to MedCityNews.

Vertex Pharmaceuticals could emerge as another competitor. The company acquired a drug candidate in the same indication earlier this year, though Vertex has not shared details on when it might move forward. OMass, launched years ago, has not yet begun clinical trials for this program, so its lead asset is not yet clear.

The funding round shows investor interest in rare disease therapies, even as the space becomes more competitive. Neurocrine’s crinecerfont, the only option available to patients, was cleared by regulators recently, setting up a race for the next treatment. OMass’s raise reflects confidence in its approach, though it still faces regulatory and clinical challenges.

For now, the startup is focused on a single disorder affecting a small patient group. How OMass expands its pipeline—or responds if Vertex enters the market—will determine its future.

Sources: medcitynews.com